Complement inhibitory therapeutics and xenotransplantation.
Nat Med
; 1(9): 967-8, 1995 Sep.
Article
em En
| MEDLINE
| ID: mdl-7585227
ABSTRACT
Once complement-mediated HAR has been inhibited, the full spectrum of cellular and antibody-mediated inflammatory and immune responses characteristic of acute and chronic rejection will need to be counter-manded. But the fact remains that if xenotransplantation is to become a clinical reality, a clinically relevant means of inhibiting complement activation will be required. Soluble complement receptor type 1 provides such a therapeutic option and an option where the dosing regimen is under the control of the physician and can be adjusted in response to the needs of the patient.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transplante Heterólogo
/
Proteínas Inativadoras do Complemento
/
Facilitação Imunológica de Enxerto
/
Ativação do Complemento
/
Rejeição de Enxerto
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
1995
Tipo de documento:
Article